Press Releases June 3, 2026 11:30 AM

Nasdaq Resumes Trading in TJGC Group Limited

Nasdaq Resumes Trading in TJGC Group Limited After Two Weeks Halt

By Priya Menon
Share
Twitter Reddit Facebook LinkedIn
TJGC

Nasdaq has announced the resumption of trading for TJGC Group Limited shares starting June 3, 2026, after trading was halted on May 15, 2026. No specific details regarding the cause for the halt or new developments have been provided in this announcement.

Nasdaq Resumes Trading in TJGC Group Limited
TJGC
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Trading for TJGC Group Limited was halted on May 15, 2026.
  • Trading resumed at 12:00 p.m. Eastern Time on June 3, 2026.
  • No additional information or reason for the trading halt was disclosed in this release.

NEW YORK, June 03, 2026 (GLOBE NEWSWIRE) -- The Nasdaq Stock Market® (Nasdaq: NDAQ) announced that trading will resume in TJGC Group Limited (Nasdaq: TJGC) at 12:00 p.m. Eastern Time on June 3, 2026. Trading in the company’s ordinary shares was halted on May 15, 2026 at 18:50:47 Eastern Time.

For news and additional information about the company, please contact the company directly or check under the company’s symbol using InfoQuotesSM on the Nasdaq® Web site.

For more information about The Nasdaq Stock Market, visit the Nasdaq Web site at http://www.nasdaq.com.

Nasdaq Contact:

Nasdaq MarketWatch
[email protected]

NDAQO


Risks

  • Lack of information about the reason for the trading halt may indicate unresolved operational or regulatory issues affecting the company.
  • Potential volatility in TJGC stock price upon resumption due to uncertainty among investors.
  • The absence of clarifying details could impact investor confidence and influence the energy/materials sectors if the company operates in those industries.

More from Press Releases

All In FutureTech Alliance Provides Strategic Updates: Hainan AIFA Digital Industrial Park, Silicon Photonics Compute Center Planning, and Cross-Border Optical Network Integration Jun 6, 2026 Cullinan Therapeutics Presents Initial Clinical Data for CLN-978, a CD19xCD3 T Cell Engager, at the EULAR 2026 Congress Jun 6, 2026 InterPrivate Investment Partners V, Inc. Announces Closing of $201.25 Million Initial Public Offering Jun 5, 2026 Bluejay Diagnostics Announces Closing of Up to $23.7 Million Private Placement Priced At-The-Market Under Nasdaq Rules Jun 5, 2026 Data at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of MannKind’s Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and Use with Automated Insulin Delivery (AID) Systems Jun 5, 2026